Neoadjuvant targeted treatment shows feasibility for limited clear-cell RCC News-Medical.net The 24 ccRCC patients in the study who received a 5 mg dose for up to 12 weeks pre-nephrectomy reported no grade 4 or 5 adverse events according to Common Terminology Criteria for Adverse Events v 4.0. Furthermore, the grade 3 and lower adverse ... Surgery promising for non-metastatic RCC with thrombus |
